Independent DSMB recommends continuing clinical trial of Berubicin without modificationEnrollment expected to be complete in early Q1 2024HOUSTON, TX / ACCESSWIRE / December 18, 2023 / CNS Pharmaceuticals, Inc.

CNSP

10 Short Squeeze Candidates: Getty Images, Genius Brands, MicroStrategy And More

By Chris Katje

February 21, 12:37 PM

Potential short squeeze plays gained steam in 2021 and continued through 2022, with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common traits that could lead to a short squeeze.

APRN

$1000 Invested In Adobe 20 Years Ago Would Be Worth This Much Today

By Benzinga Insights

November 8, 11:25 AM

Adobe (NASDAQ:ADBE) has outperformed the market over the past 20 years by 9.03% on an annualized basis producing an average annual return of 16.41%. Currently, Adobe has a market capitalization of $140.61 billion.

ADBE

Benchmark Downgrades Getty Images Holdings to Hold

Related Posts

Oppenheimer Maintains Outperform on Estee Lauder Cos, Raises Price Target to $300

CNS Pharmaceuticals Announces Successful Interim Analysis Of Efficacy And Safety Data In Potentially Pivotal Study Of Berubicin; Independent DSMB Recommends Continuing Clinical Trial Of Berubicin Without Modification

10 Short Squeeze Candidates: Getty Images, Genius Brands, MicroStrategy And More

$1000 Invested In Adobe 20 Years Ago Would Be Worth This Much Today